Erin Dunbar, MD
Medical Oncology · Atlanta, GANPI 1235298779
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,325 of the $34,771 with a category attached, or 75.7%. It is spread thinly across 26 manufacturers, the largest accounting for just 23.8%.
Across 108 payments — averaging $321.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- GT Medical Technologies, Inc$7K
- Novocure Inc.$6K
- Telix Pharmaceuticals$5K
- Servier Pharmaceuticals LLC$3K
- Brainlab, Inc.$1K
- plus $4K from 20 others
Across 11 payments — averaging $3954.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$27K
- Novocure GmbH$17K
What the payments were for
- Consulting fees$26,32576%
- Speaking & faculty fees$1,7665%
- Travel & lodging$3,31810%
- Food & beverage$3,36310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $8,290 |
| GT Medical Technologies, Inc | 5 | $6,912 |
| Novocure Inc. | 24 | $5,894 |
| Telix Pharmaceuticals | 13 | $4,845 |
| Servier Pharmaceuticals LLC | 2 | $3,349 |
| Brainlab, Inc. | 13 | $1,347 |
| R-pharm US LLC | 2 | $1,323 |
| Bayer | 1 | $1,250 |
| Biogen | 1 | $850 |
| Integra Lifesciences Corporation | 4 | $105 |
| Johnson & Johnson(2 entities) | 3 | $87 |
| Novartis | 3 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Coherus Oncology, Inc. | 2 | $49 |
| AstraZeneca(2 entities) | 2 | $46 |
| Kyowa Kirin, Inc. | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Globus Medical | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Neurelis, Inc. | 1 | $23 |
| Caris MPI, Inc. | 1 | $20 |
| Merit Medical Systems Inc | 1 | $19 |
| Amgen | 1 | $18 |
| Irras USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GammaTile$6,881
- Venclexta$6,272
- ILLUCCIX$6,000
- Voranigo$3,325
- Optune$3,172
- Ixempra$1,323
- Vitrakvi$1,250
- Image Guided Surgical Device$760
- Surgical planning and navigation radiation treatment planning and positioning$100
How this compares
$34,771 in reported general payments places this provider in the 85th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KoselugoSelumetinib Sulfate | 30 | $670,091 |
| GleostineLomustine | 29 | $21,246 |
| Dexamethasone | 95 | $2,184 |
| Leucovorin Calcium | 12 | $1,986 |
| Levetiracetam | 99 | $1,331 |
| Famotidine | 116 | $1,018 |
| Gabapentin | 84 | $907 |
| Duloxetine Hcl | 33 | $808 |
| ValacyclovirValacyclovir Hcl | 11 | $535 |
| Ondansetron OdtOndansetron | 25 | $450 |
| Methylphenidate Hcl | 16 | $298 |
| Prochlorperazine Maleate | 16 | $202 |
| Hydrocortisone | 11 | $185 |
| Memantine Hcl | 21 | $182 |
| Pregabalin | 12 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaKoselugo | $46 | $670,09130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Atlanta
- Nabil SabaAtlanta$225K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Olumide GbolahanAtlanta$32K
- Bradley CarthonAtlanta$31K
- Joseph MaakaronAtlanta$29K
- Ruth SacksAtlanta$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.